We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

49 hedge funds and large institutions have $212M invested in Protara Therapeutics in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

36% more capital invested

Capital invested by funds: $156M → $212M (+$56.3M)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

2% more funds holding

Funds holding: 48 → 49 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10.77% less ownership

Funds ownership: 89.06% → 78.29% (-11%)

Holders
49
Holders Change
+1
Holders Change %
+2.08%
% of All Funds
0.87%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
6
Increased
20
Reduced
12
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$3.07M
2
BlackRock
BlackRock
New York
+$1.93M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.82M
4
Artisan Partners
Artisan Partners
Wisconsin
+$1.73M
5
State Street
State Street
Massachusetts
+$582K

Top Sellers

1
FCM
Farallon Capital Management
California
-$7.15M
2
CH
CVI Holdings
Delaware
-$2.84M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$2.71M
4
CAM
Cormorant Asset Management
Massachusetts
-$2.16M
5
CAC
Cowen and Company
New York
-$2.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$61.9M – – –
DM
2
Deerfield Management
New York
$18.9M – – –
IC
3
Ikarian Capital
Texas
$15.7M -$1.57M -72,901 -10%
RSCM
4
Rock Springs Capital Management
Maryland
$15.6M -$9.1K -422 -0.1%
PA
5
Perceptive Advisors
New York
$14.7M – – –
O
6
OrbiMed
New York
$10.9M – – –
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$10.5M -$312K -14,495 -3%
Artisan Partners
8
Artisan Partners
Wisconsin
$9.12M +$1.73M +80,349 +27%
CAM
9
Cormorant Asset Management
Massachusetts
$8.47M -$2.16M -100,000 -22%
Franklin Resources
10
Franklin Resources
California
$8.47M +$216 +10 +0%
BC
11
Boxer Capital
California
$5.07M – – –
BBA
12
Baker Bros. Advisors
New York
$4.83M – – –
BlackRock
13
BlackRock
New York
$4.4M +$1.93M +89,656 +97%
Vanguard Group
14
Vanguard Group
Pennsylvania
$3.92M +$3.07M +142,373 +729%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$2.54M +$1.82M +84,598 +417%
MS
16
Maven Securities
Jersey
$2.32M -$108K -5,000 -5%
Alyeska Investment Group
17
Alyeska Investment Group
Illinois
$1.8M -$2.71M -125,595 -63%
Northern Trust
18
Northern Trust
Illinois
$1.53M +$567K +26,318 +71%
BFM
19
Boothbay Fund Management
New York
$1.41M -$139K -6,457 -10%
Millennium Management
20
Millennium Management
New York
$1.34M +$374K +17,331 +46%
State Street
21
State Street
Massachusetts
$1.21M +$582K +27,015 +117%
TLP
22
Tri Locum Partners
New York
$950K +$846K +39,225 New
EP
23
Eversept Partners
New York
$879K – – –
Two Sigma Investments
24
Two Sigma Investments
New York
$692K +$398K +18,480 +183%
TD Asset Management
25
TD Asset Management
Ontario, Canada
$610K – – –
1
2 3

TARA Hedge Fund Activity: Q4 2020 in Review

49 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2020, worth a combined $212M — up 36% from $156M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TARA positions and 5 closed out — a net gain of 1 holder — while 20 added to existing stakes and 12 trimmed.

The largest buyer was Vanguard Group, adding an estimated $3.07M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $7.15M sold.

  • 49 institutional investors held Protara Therapeutics (TARA) as of Q4 2020, up from 48 in Q3 2020.
  • Funds reported $212M of Protara Therapeutics stock for Q4 2020, up 36% quarter-over-quarter.
  • 6 funds opened new Protara Therapeutics positions in Q4 2020 and 5 closed out, a net change of +1 holder.
  • The largest Protara Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $3.07M added.
  • The largest Protara Therapeutics seller in Q4 2020 was Farallon Capital Management, an estimated $7.15M sold.

Based on aggregated 13F filings for Q4 2020.